A few companies in the healthcare sector are undergoing developments leading to emergence of significant growth opportunities. No wonder, astute investors are recognising and taking advantage of this to add these to their portfolio
Best emerging ASX Healthcare Stocks
Orthocell Limited (ASX: OCC)
Cogstate Limited (ASX: CGS)
Race Oncology Limited (ASX: RAC)
Cleo Diagnostics Limited (ASX: COV)
Orthocell Limited (ASX: OCC)
is working towards the implementation of its flagship nerve repair device, RemplirTM. dsuccess rate. This study will be used by the company to support US RemplirTM sales rollout targeting a market of USD 1.6 billion. Expanding the market, the company plans to submit to the regulatory needs by the fourth quarter of 2025 in the UK and Europe. The product has been introduced to Urologists in Australia to test the use of Remplir in nerve-sparing RARP, which will further r the market of this product. Moreover, the company has shown five consecutive years of growth in revenue, reporting $2.73 million in June 2025. It has no debts and no royalties to pay, which states its strong financial health to move forward with operations.
Cogstate Limited (ASX: CGS)
has delivered robust performance over the years. Revenue of $53.1 million was up by 22 per cent, mainly driven by growth in revenues from Clinical trials. Profit before tax reported at $13.9 per cent. The margins have expanded, reporting gross margin at 61 per cent, EBITDA Margin at 30 per cent, and EBIT margin of 25 per cent. This reflects the company’s efficient cost management. CGS has declared an annual dividend of $0.02 per ordinary share (fully franked). Cogstate has a key catalyst set for FY26 for expansion, like the commercial launch of its first AI-powered product, and potential in trials of Alzheimer’s. With a strong balance sheet, support and proven operating leverage, it is set for growth.
Race Oncology Limited (ASX: RAC)
has discovered that its cancer drug, bisantrene, exists in three different forms (Isomers), but only one of them can deliver strong anticancer effects. To secure this discovery, the company has applied for three patent applications covering the chemical structure of the active isomer as well as its manufacturing use in treatment and storage. If this patent is secured, then it will give a commercial breakthrough by attracting pharmaceutical partners and, strong position in licensing discussions. Overall, this will increase the market value of its drug pipeline.
Cleo Diagnostics Limited (ASX: COV)
has received positive feedback from the FDA on its second-round submission of its Ovarian Cancer Pre-Surgical Triage test. The company is progressing towards the commercialisation of its Ovarian Cancer detection product, which is expected in 2025. With positive feedback, it has reduced its regulatory risk for 510(K) submissions. Moreover, it has completed in-house testing of its prototype assay kits manufactured in partnership. Cleo has secured access to significant worldwide ovarian cancer biobanks, including the UKCTOCS and PLCO resources in the UK and the U.S., providing patient samples to validate its test and support regulatory submissions. It is well capitalised with $6.46 million and has sufficient funding for the development of its key products.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
